Examine This Report on Eprenetapopt
Sufferers who have participated in almost any clinical investigation using an investigational drug in just one thirty day period before screening or inside of 5 50 %-life in the investigational cure whichever is more time.The anti-PD1 antibody camrelizumab continues to be applied with A further epigenetic inhibitor decitabine in R/R HL and nearly 7